Hospital stocks rose after cancer drug price caps imposed

Why did hospital stocks rise after the price caps?

Investors treated the cap as good news because it ended years of uncertainty over sweeping price controls. The cap covers only non-scheduled anti-cancer drugs, a narrow slice of hospital revenue. History supports their optimism: after 2017 stent caps, hospitals recovered margins within 12-15 months by raising procedure charges, and Apollo restored profitability within quarters. Investors bet the pattern repeats.

Why would investors celebrate if hospital profits should fall?

Because investors believe the cap is small enough that hospitals can recover the lost margin, as they did after stents were capped in 2017. Then, hospitals raised procedure charges; the CEO of Narayana Hrudayalaya (a hospital chain) admitted costs rose 15%, and Apollo hiked angioplasty bills from Rs 1.25 lakh to Rs 1.4 lakh. The pattern points to offsetting the hit within 12-15 months.

How big is the pharmacy business for hospitals?

Brokerages estimate pharmacy sales make up roughly 15-20% of hospital revenue. That's a significant slice, but the actual hit from the price cap is smaller than it sounds, since insured patients pay pre-negotiated package rates that already discount drug prices.

Did the stent cap actually save patients money?

No, not clearly. After the 2017 stent cap, package costs fell at Apollo and Fortis but stayed the same at Narayana Hrudayalaya (a hospital chain). Hospitals raised procedure charges, like Apollo hiking from Rs 1.25 lakh to Rs 1.4 lakh, and recovered margins within 12-15 months, so patient savings were limited or erased.

Do hospitals raise other prices after each government cap?

Yes, the pattern repeats. After the 2017 stent price cap, hospitals like Apollo hiked angioplasty procedure charges from Rs 1.25 lakh to Rs 1.40 lakh, offsetting lost margins within 12-15 months. Analysts expect hospitals to similarly raise other charges this time, assuming they can pass on the impact.

Why would the market assume hospitals can pass on costs?

The market sees a pattern: when the government capped stent prices by 85% in 2017, hospitals offset the loss by hiking procedure charges within 12-15 months. Apollo restored its margins within a few quarters. Investors expect similar moves now, so they see the drug cap's impact as temporary and manageable.

How much will the cancer drug cap save patients?

The government estimates the 30% cap on trade margins, the gap between a drug's cost and what patients pay, could cut prices of some cancer medicines by up to 70% and save patients about Rs 2,500 crore a year. The cap applies only to non-scheduled anti-cancer drugs, extending an earlier limit on select oncology drugs.

What happened after the 2017 stent price cap?

In February 2017, the government capped cardiac stent prices by 85%. A year later, patients were still paying the same for angioplasty. Hospitals hiked procedure costs to recover lost margins. Apollo raised its angioplasty charge from Rs 1.25 lakh to Rs 1.4 lakh, and the doctor's share rose from 15% to 30%.

Do brokers think hospital stocks are cheap now?

Yes. Jefferies notes hospital stocks trade at about 21-25 times FY28 estimated EV/EBITDA, down from 25-35 times a year ago, a significant de-rating. Historically, regulatory overhangs have weighed on stocks for 3-6 months before recovery begins. After the 2017 stent caps, Apollo delivered 3% returns in the following year. After the PIL in February 2024, stocks initially fell but generated positive returns within six months.

What is EBITDA?

EBITDA is a rough measure of a hospital's profit from daily operations, before interest, taxes, depreciation, and amortisation. Analysts use it to estimate how much a price cap might hurt business. For example, Jefferies (an analyst firm) calculates a 2-5% EBITDA impact under various price-cap scenarios, assuming hospitals can't pass costs on.

Is the regulatory threat now narrower?

Yes. The cap applies only to non-scheduled anti-cancer drugs, not to consumables, stents, or procedure charges. Emkay (an analyst firm) says a blanket cap on drug margins is unlikely due to the difficulty of covering all non-scheduled drugs across the pharma ecosystem, so the uncertainty has reduced.